Skip to main content

CASE REPORT article

Front. Immunol.
Sec. Multiple Sclerosis and Neuroimmunology
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1535782
This article is part of the Research Topic Emerging Therapeutic Potential of Plant-Derived Compounds in Neuroinflammatory Diseases View all articles

Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis

Provisionally accepted
David Qixiang Chen David Qixiang Chen 1Jose Adalberto Dominguez Inzunza Jose Adalberto Dominguez Inzunza 2Juan Manuel Valle Uzeta Juan Manuel Valle Uzeta 3Abhiram Pushparaj Abhiram Pushparaj 1,4Jonathan E Dickinson Jonathan E Dickinson 2*
  • 1 Scientific Advisory, Ambio Life Sciences, Vancouver, Canada
  • 2 Board of Directors, Ambio Life Sciences, Vancouver, Canada
  • 3 Medical Department, Ambio Life Sciences, Vancouver, British Columbia, Canada
  • 4 Consulting Department, +ROI Regulatory Advisory, Toronto, Ontario, Canada

The final, formatted version of the article will be published soon.

    Multiple sclerosis (MS) is a debilitating neurodegenerative disease characterized by demyelination and neuronal loss. Traditional therapies often fail to halt disease progression or reverse neurological deficits. Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. Patient A demonstrated substantial lesion shrinkage and decreased Apparent Diffusion Coefficient (ADC) values, suggesting remyelination and reduced inflammation. Both patients exhibited cortical and subcortical alterations, particularly in regions associated with pain and emotional processing. These findings suggest that ibogaine may promote neuroplasticity and modulate neurocircuitry involved in MS pathology.

    Keywords: Ibogaine, Noribogaine, Multiple Sclerosis, Psychedelic medicine, Neuroregeneration, Neuroimaging

    Received: 27 Nov 2024; Accepted: 20 Jan 2025.

    Copyright: © 2025 Chen, Dominguez Inzunza, Valle Uzeta, Pushparaj and Dickinson. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Jonathan E Dickinson, Board of Directors, Ambio Life Sciences, Vancouver, Canada

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.